Literature DB >> 10928963

Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

W D Hirst1, J A Minton, S M Bromidge, S F Moss, A J Latter, G Riley, C Routledge, D N Middlemiss, G W Price.   

Abstract

SB-258585 (4-Iodo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-benzen esulphonamide) is a high affinity ligand at 5-HT(6) receptors. It displays over 100 fold selectivity for the 5-HT(6) receptor over all other 5-HT receptors tested so far. SB-258585 has been radiolabelled, to high specific activity, for its characterization as a 5-HT(6) receptor selective radioligand. [(125)I]-SB-258585 bound, with high affinity, to a single population of receptors in a cell line expressing human recombinant 5-HT(6) receptors. Kinetic and saturation binding experiments gave pK(D) values of 9.01+/-0.09 and 9.09+/-0.02, respectively. In membranes derived from rat or pig striatum and human caudate putamen, [(125)I]-SB-258585 labelled a single site with high levels (>60%) of specific binding. Saturation analysis revealed pK(D) values of 8.56+/-0.07 for rat, 8.60+/-0.10 for pig and 8.90+/-0.02 for human. B(max) values for the tissues ranged from 173+/-23 and 181+/-25 fmol mg(-1) protein in rat and pig striatum, respectively, to 215+/-41 fmol mg(-1) protein in human caudate putamen. The pK(i) rank order of potency for a number of compounds, determined in competition binding assays with [(125)I]-SB-258585, at human caudate putamen membranes was: SB-271046>SB-258585>SB-214111>methiothepin>clozapine>5-Me-OT>5-HT>Ro 04-6790>mianserin>ritanserin=amitriptyline>5-CT>mesulergine. Similar profiles were obtained from pig and rat striatal membranes and recombinant 5-HT(6) receptors; data from the latter correlated well with [(3)H]-LSD binding. Thus, [(125)I]-SB-258585 is a high affinity, selective radioligand which can be used to label both recombinant and native 5-HT(6) receptors and will facilitate further characterization of this receptor subtype in animal and human tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928963      PMCID: PMC1572217          DOI: 10.1038/sj.bjp.0703458

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Central distribution and function of 5-HT6 receptor subtype in the rat brain.

Authors:  M Yoshioka; M Matsumoto; H Togashi; K Mori; H Saito
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

2.  Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system.

Authors:  C Gérard; M P Martres; K Lefèvre; M C Miquel; D Vergé; L Lanfumey; E Doucet; M Hamon; S el Mestikawy
Journal:  Brain Res       Date:  1997-01-23       Impact factor: 3.252

3.  Identification of a human 5-HT6 receptor variant produced by alternative splicing.

Authors:  M A Olsen; S P Nawoschik; B R Schurman; H L Schmitt; M Burno; D L Smith; L E Schechter
Journal:  Brain Res Mol Brain Res       Date:  1999-02-05

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.

Authors:  F G Boess; C Riemer; M Bös; J Bentley; A Bourson; A J Sleight
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

6.  Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.

Authors:  J C Bentley; A Bourson; F G Boess; K C Fone; C A Marsden; N Petit; A J Sleight
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

7.  Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats.

Authors:  C Gérard; S el Mestikawy; C Lebrand; J Adrien; M Ruat; E Traiffort; M Hamon; M P Martres
Journal:  Synapse       Date:  1996-07       Impact factor: 2.562

8.  Involvement of 5-HT6 receptors in nigro-striatal function in rodents.

Authors:  A Bourson; F G Boess; M Bös; A J Sleight
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

9.  Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.

Authors:  A J Sleight; F G Boess; M Bös; B Levet-Trafit; C Riemer; A Bourson
Journal:  Br J Pharmacol       Date:  1998-06       Impact factor: 8.739

10.  5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.

Authors:  S M Bromidge; A M Brown; S E Clarke; K Dodgson; T Gager; H L Grassam; P M Jeffrey; G F Joiner; F D King; D N Middlemiss; S F Moss; H Newman; G Riley; C Routledge; P Wyman
Journal:  J Med Chem       Date:  1999-01-28       Impact factor: 7.446

View more
  18 in total

1.  Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.

Authors:  C Routledge; S M Bromidge; S F Moss; G W Price; W Hirst; H Newman; G Riley; T Gager; T Stean; N Upton; S E Clarke; A M Brown; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 2.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

3.  Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study.

Authors:  Donatella Marazziti; Stefano Baroni; Andrea Pirone; Gino Giannaccini; Laura Betti; Lara Schmid; Elena Vatteroni; Lionella Palego; Franco Borsini; Fabio Bordi; Ilaria Piano; Claudia Gargini; Maura Castagna; Mario Catena-Dell'osso; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2012-01-26       Impact factor: 3.996

4.  Deconstructing 5-HT6 receptor effects on striatal circuit function.

Authors:  D Eskenazi; M Brodsky; J F Neumaier
Journal:  Neuroscience       Date:  2015-04-28       Impact factor: 3.590

Review 5.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging.

Authors:  Guillaume Becker; Julie Colomb; Véronique Sgambato-Faure; Léon Tremblay; Thierry Billard; Luc Zimmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

Review 7.  Measuring endogenous 5-HT release by emission tomography: promises and pitfalls.

Authors:  Louise M Paterson; Robin J Tyacke; David J Nutt; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-28       Impact factor: 6.200

8.  Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies.

Authors:  Małgorzata Dukat; Philip D Mosier; Renata Kolanos; Bryan L Roth; Richard A Glennon
Journal:  J Med Chem       Date:  2008-01-18       Impact factor: 7.446

9.  Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.

Authors:  Florence Loiseau; Anne Dekeyne; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2007-10-06       Impact factor: 4.530

10.  SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.

Authors:  David R Thomas; Sergio Melotto; Mario Massagrande; Andrew D Gribble; Phillip Jeffrey; Alexander J Stevens; Nigel J Deeks; Peter J Eddershaw; Susan H Fenwick; Graham Riley; Tania Stean; Claire M Scott; Matthew J Hill; Derek N Middlemiss; Jim J Hagan; Gary W Price; Ian T Forbes
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.